BioSpace News Archive

Castle Biosciences, Inc. today announced real-world study data demonstrating that use of IDgenetix® to guide medication management can significantly improve medication response and remission rates in patients diagnosed with moderate to severe depression, compared to current standard-of-care treatment.

Diality Inc. today announced the appointment of healthcare veteran Robert Funari to its board of directors.

Rocket Pharmaceuticals, Inc. today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to RP-A501, the Company’s investigational adeno-associated virus (AAV)-based gene therapy for the treatment of Danon Disease.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), to be presented at the upcoming Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 31 - June 4, 2023, in Aurora, Colorado.

JSR Life Sciences today announced that KBI Biopharma, Inc. (KBI) and Selexis SA are consolidating as one organization under the KBI Biopharma name to accelerate innovation and growth for its global biopharma customers.

scPharmaceuticals Inc. announced that John Tucker, President & Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference, which is being held June 7-9 in New York.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces approval from the Australian Human Research Ethics Committee (HREC) to conduct a Phase 1 study with its novel, oral, broad-spectrum 3CL protease inhibitor CDI-988 as a potential treatment for COVID-19.

Vaxart, Inc. announced it is launching an investor communication program that will give investors the ability to ask questions of Company management.

Ventyx Biosciences, Inc. announced that Company executives will participate in the following upcoming investor conferences.